Literature DB >> 34585743

First use of the anti-VWF nanobody caplacizumab to treat iTTP in pregnancy.

Lucas Kühne1,2, Linus A Völker1,2, Henning Hagmann1,2, Holger Hägele1,2, Thomas Osterholt1,2, Dennis A Eichenauer3, Andreas Thomas4, Johanna Breuer4, Berthold Grüttner5, Ingo Gottschalk5, Martin Kann1,2, Thomas Benzing1,2, Mario Thevis4, Annette M Müller6, Paul T Brinkkoetter1,2.   

Abstract

Entities:  

Keywords:  platelets; pregnancy; thrombocytopenia; thrombotic haemolytic anaemia

Mesh：

Substances：

Year:  2021        PMID： 34585743     DOI： 10.1111/bjh.17833

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  Maternal and fetal outcomes of pregnancy occurring after a diagnosis of immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Jenna Brown; Bindu Potugari; Marshall A Mazepa; Ruhail Kohli; Alison R Moliterno; Robert A Brodsky; Jason A Vaught; Richard Burwick; Shruti Chaturvedi
Journal:  Ann Hematol       Date:  2022-08-06       Impact factor: 4.030

2.  European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis.

Authors:  Kathrin Eller; Paul Knoebl; Sevcan A Bakkaloglu; Jan J Menne; Paul T Brinkkoetter; Leonie Grandt; Ursula Thiem; Paul Coppo; Marie Scully; Maria C Haller
Journal:  Nephrol Dial Transplant       Date:  2022-06-23       Impact factor: 7.186

Review 3.  Diagnosis and treatment of thrombotic microangiopathy.

Authors:  Gemma L Thompson; David Kavanagh
Journal:  Int J Lab Hematol       Date:  2022-09       Impact factor: 3.450
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.